ORGO Q2 2021 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$123M+78.6% YoY

Gross Profit

$93M75.7% margin

Operating Income

$24M19.1% margin

Net Income

$21M16.8% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+20.1%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$356M

Total Liabilities

$177M

Stockholders' Equity

$179M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$123M	$69M	+78.6%
Gross Profit	$93M	$49M	+90.6%
Operating Income	$24M	-$2M	+1147.4%
Net Income	$21M	-$5M	+500.4%

Revenue Segments

Advanced Wound care

$111M90%

Surgical and Sports Medicine

$12M10%